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Background: Recent studies have reported an association between both higher and lower levels of hemoglobin
A1c (HbA1c) and higher mortality of diabetes patients. Like diabetes, carotid atherosclerosis is a well known
lifestyle-related disease. However, no studies have yet reported an association between HbA1c levels and carotid
atherosclerosis.
Methods: We conducted a cross-sectional study of 1,150 Japanese elderly men aged ≥60 years who were undergoing
general health checkups. Carotid atherosclerosis was defined as a carotid intima-media thickness (CIMT) ≥1.1 mm. Since
body mass index (BMI) is regarded as a cardiovascular risk factor that exerts a strong influence on both HbA1c levels
and carotid atherosclerosis, we performed a stratified analysis of this risk based on BMI.
Results: Using the intermediate HbA1c quintile as a reference group, the groups in the lowest HbA1c quintiles showed
a significantly higher risk of carotid atherosclerosis in patients with low BMI (≤23 kg/m2) vs. no increased risk in those
with high BMI (>23 kg/m2). The association of HbA1c with carotid atherosclerosis became slightly stronger when these
analyses were limited to subjects who were not taking glucose-lowering medications or medications for hyperlipidemia
and cardiovascular disease. After adjusting for classical cardiovascular risk factors, adjusted odds ratios (ORs) for carotid
atherosclerosis were 1.36 (0.84 to 2.20) for total subjects, 2.29 (1.12 to 4.66) for low-BMI groups, and 0.68 (0.33 to 1.41)
for high-BMI groups.
Conclusions: Lower HbA1c level is a significant risk factor for carotid atherosclerosis in rural community-dwelling
elderly Japanese men with low, but not high BMI, particularly in those not taking glucose-lowering medication.Introduction
The exact nature of the association between hemoglobin
A1c (HbA1c) and cardiovascular disease remains contro-
versial. Previous studies established the existence of a linear
relationship between HbA1c and cardiovascular mortality
for type 2 diabetes [1], type 1 diabetes [2], and non-
diabetic subjects [3],while other studies found that both
low and high mean HbA1c values were associated with in-
creased all-causal mortality and cardiac events in diabetes
patients [4,5]. The Norfolk prospective population study* Correspondence: simizicyuu@yahoo.co.jp
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unless otherwise stated.detected a J-shaped association between HbA1c concentra-
tions and incidence of stroke [6]. Furthermore, an increase
in carotid intima-media thickness (CIMT) was reported to
be an independent risk factor for stroke [7]. However, no
studies have reported on the association between
HbA1c levels and carotid atherosclerosis evaluated by
CIMT. Our previous study that investigated the associ-
ation between atherosclerosis (evaluated using CIMT)
and diabetes (defined as HbA1c (NGSP: National Gly-
cohemoglobin Standardization Program) ≥6.5% and/or
initiation of glucose-lowering medication or insulin
therapy) in a community-based sample of subjects di-
vided into tertiles according to triglycerides-to-HDL
cholesterol ratio (TG-HDL) levels reported that onlyl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and low TG-HDL were at significant risk for atheroscler-
osis [8]. We also reported a significant inverse association
between low-TG-HDL diabetes and body mass index
(BMI) and a significant positive association between high-
TG-HDL diabetes and BMI in a community-based sample
[9]. These studies indicate that BMI status might influence
the association between HbA1c and carotid atheroscler-
osis. We therefore hypothesized that not only higher but
also lower HbA1c is a risk factor for carotid atheroscler-
osis and that BMI status may influence this association.
To investigate possible associations, we conducted a
cross-sectional study of 1,150 elderly Japanese men aged




The original sample included 1,185 men aged 60 to
94 years residing in a rural community on the western
Japan Goto Islands. Subjects were recruited between
2005 and 2012. A total of 35 individuals with missing
data (6 individuals without BMI data, 3 individuals with-
out blood pressure data, 23 without alcohol consumption
data, and 3 individuals without blood test data) were ex-
cluded, leaving a total of 1,150 men for enrolment in this
study. The mean age of the study sample was 70.1 years
(±6.8 SD; range 60 to 94). This study was approved by the
Ethics Committee for Human Use of Nagasaki University
(project registration number 0501120073).
Data collection and laboratory measurements
Systolic and diastolic blood pressures at rest in a sitting
position were recorded by trained technicians using a
blood pressure measuring device (HEM-907; Omron,
Kyoto, Japan). Briefly, height in stocking feet and weight
in light clothing were measured with an automatic body
composition analyzer (BF-220; Tanita, Tokyo, Japan)
prior to blood drawing. Trained interviewers obtained
information on smoking status (never smoker, former
smoker, current smoker), alcohol consumption [non-
drinker and current light-to-moderate drinker (one to
six times/week), current heavy drinker (every day)],
medical history, use of medications for cardiovascular
disease, use of medication for hyperlipidemia, use of an-
tihypertensive agents, and use of medications for dia-
betes mellitus. Fasting blood samples were collected in
sodium fluoride tubes and siliconized tubes. Samples
from siliconized tubes were used for serum separation
and centrifugation following blood coagulation. All mea-
surements were conducted using standard laboratory
procedures at SRL, Inc. (Tokyo, Japan). HbA1C was mea-
sured with the latex agglutination method [10] using
samples from the sodium fluoride tubes. Serumconcentration of HDL-cholesterol was measured using
the direct method, serum triglycerides (TG) and creatin-
ine were measured using the enzyme method, and aspar-
tate aminotransferase (AST) was measured using the
JASCC standardization method. HbA1c (NGSP) level
was calculated using the following equation, which was
recently proposed by a working group of the Japanese
Diabetes Society (JDS): HbA1c(NGSP) = HbA1c(JDS) ×
1.02 + 0.25% [11]. The glomerular filtration rate (GFR)
was estimated by using an established method with three
variations recently proposed by a working group of the
Japanese Chronic Kidney Disease Initiative [12], based
on which GFR (mL/min/1.73 m2) = 194 × (serum creatin-
ine (enzyme method))−1.094 × (age)−0.287.
Carotid B-mode ultrasound imaging
Measurement of CIMT by ultrasonography of the left
and right carotid arteries was performed by two medical
doctors (NT and MN) using a LOGIQ Book XP with a
10-MHz transducer (GE Healthcare, Milwaukee, WI,
USA) that was programmed with the IMT measurement
software Intimascope (Cross Media Ltd., Tokyo, Japan)
[13]. The protocol that was used has been described in de-
tail elsewhere [14]. The values for right and left CIMT
without plaque measurement were calculated, and the
higher CIMT value was used for the analysis. Based on
previous studies [8,15,16], we defined carotid atheroscler-
osis as a CIMT ≥1.1 mm. Intra-observer variation agree-
ment for CIMT (NT, n = 32) was 0.91 (P value (P) <0.01),
and inter-observer variation agreement (NT vs. MN, n =
41) was 0.78 (P < 0.01).
Statistical analysis
Differences in age-adjusted mean values or prevalence of
potential confounding factors in relation to HbA1c levels
were calculated using ANOVA or logistic regression
models. Odds ratios (ORs) and 95% confidence intervals
(CIs) for carotid atherosclerosis (CIMT ≥ 1.1 mm) asso-
ciated with HbA1c levels were calculated with the aid of
logistic regression models. In addition, subjects were
stratified by BMI status since a relatively high BMI is
regarded as one of the most common cardiovascular risk
factors. Since the World Health Organization (WHO)
identified BMI ≥23 kg/m2, which corresponds to the me-
dian BMI values of the men in our study, as an indicator
of enhanced risk of disease in Asian populations [17],
the BMI cutoff point was set at 23 kg/m2. Furthermore,
analyses were restricted to subjects who were not taking
glucose-lowering medications or medications for hyperlip-
idemia and cardiovascular disease. Two different ap-
proaches were used to adjust for confounding factors. The
first was adjustment only for age. For the second ap-
proach, we included other potential confounding factors
such as smoking status, alcohol consumption, systolic
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medication use (no, yes), taking glucose-lowering medi-
cation (no, yes), taking medication for hyperlipidemia
(no, yes), taking medication for cardiovascular disease
(no, yes), HDL-cholesterol (mg/dL), TG (mg/dL), AST
(IU/L), and GFR (mL/min/1.73 m2). Because glucose-
lowering medication and taking medication for hyper-
lipidemia and cardiovascular disease might strongly
confound these associations [7,18,19], we restricted fur-
ther analysis to subjects not taking glucose-lowering
medication or medication for hyperlipidemia and car-
diovascular disease. All statistical analyses were per-
formed with the SAS system for Windows (version 9.3;
SAS Inc., Cary, NC). All P values (P) and P for the trend
(P) for statistical tests were two-tailed, with values of
<0.05 regarded as being statistically significant.
Results
Clinical characteristics of the subjects
The clinical characteristics of the subjects in this study
are summarized in Table 1. HbA1c levels were signifi-
cantly and inversely associated with serum creatinine
and significantly and positively associated with GFR for
total subjects and those with low or high BMI. Addition-
ally, a J-shaped association between HbA1c levels and
history of cardiovascular disease was observed for total
subjects and those with low, but not high BMI.
Association between carotid atherosclerosis and HbA1c
Table 2 shows ORs and 95% CIs for carotid atherosclerosis
in relation to HbA1c levels for the study sample. Using
the data for the median HbA1c level quintile as reference,
lower HbA1c level was found to be a significant risk factor
for carotid atherosclerosis in subjects with low BMI but
not with high BMI, and no significant association was
noted even when HbA1c levels were at their highest. With
the median HbA1c level (Q3) as the reference group, the
multi-adjusted ORs (95% CI) for carotid atherosclerosis in
subjects with low BMI were 1.78 (0.92 to 3.44) for Q1 and
2.05 (1.06 to 3.96) for Q2, while for subjects with high
BMI, the corresponding values were 0.66 (0.35 to 1.27)
and 0.94 (0.51 to 1.73), respectively.
Clinical characteristics limited to subjects with HbA1c (≤Q3)
We also investigated the effects of interaction between
HbA1c and two BMI categories, low BMI and high BMI,
on carotid atherosclerosis. Significant interaction was seen
between HbA1c and BMI status among subjects with
HbA1c (≤Q3) but not with HbA1c (≥Q3), with the
multivariable-adjusted P values for the effect of this inter-
action on carotid atherosclerosis of P = 0.027 for subjects
with HbA1c (≤Q3) and P = 0.951 for HbA1c (≥Q3).
Since the significant interaction between HbA1c and
the two BMI categories on carotid atherosclerosis wasobserved only among subjects with HbA1c (≤Q3) but
not with HbA1c (≥Q3), we conducted a further analysis
to evaluate the age-adjusted clinical characteristics lim-
ited to subjects with HbA1c (≤Q3) (Table 3). Significant
positive association between HbA1c levels and GFR
values was limited to subjects with low BMI. For these
subjects, the age-adjusted mean value of GFR for each
HbA1c level was 62.7 mL/min/1.73 m2 for Q1, 68.4 mL/
min/1.73 m2 for Q2, and 69.0 mL/min/1.73 m2 for Q3
(P = 0.020), while for subjects with high BMI, the corre-
sponding values were 64.8 mL/min/1.73 m2, 66.4 mL/
min/1.73 m2, and 66.0 mL/min/1.73 m2 (P = 0.792),
respectively.
Although no significant associations were observed in
the analysis with regard to HbA1c levels and current-
drinker status, an inverse association was observed for
subjects with low BMI, whereas a positive association
was observed for subjects with high BMI. The age-
adjusted prevalence of current-drinker status for each
HbA1c level was 60.6% for Q1, 50.4% for Q2, and 47.4%
for Q3 (P = 0.121), while for subjects with high BMI, the
corresponding values were 43.7%, 54.1%, and 55.9% (P =
0.179), respectively.
Association between carotid atherosclerosis and HbA1c
in subjects not taking glucose-lowering medication or
medication for hyperlipidemia and cardiovascular disease
We also investigated the associations in subjects who
had not taken glucose-lowering medication or medica-
tion for hyperlipidemia and cardiovascular disease
(Table 4). For subjects with HbA1c (≤Q3), the associ-
ation between HbA1c level and carotid atherosclerosis
became slightly stronger. With median HbA1c level
(Q3) as the reference group, the multi-adjusted ORs
(95%CI) of carotid atherosclerosis for subjects with low
BMI were 2.29 (1.12 to 4.66) for Q1 and 2.15 (1.05 to
4.39) for Q2, while for subjects with high BMI, the cor-
responding values were 0.68 (0.33 to 1.41) and 1.09 (0.55
to 2.16), respectively.
The multivariable-adjusted P values for the correspond-
ing interaction with carotid atherosclerosis were P = 0.020
for subjects with HbA1c (≤Q3) and P = 0.775 for those
with HbA1c (≥Q3).
Discussion
Our findings demonstrate that lower HbA1c levels con-
stitute a significant risk for carotid atherosclerosis in
subjects with low BMI but not in those with high BMI.
These associations were also observed in subjects who
did not take glucose-lowering medication.
Our previous study reported a significant positive as-
sociation between BMI and patients with diabetes of the
type that carries a risk of atherosclerosis and an inverse
association in patients with diabetes of the type that
Table 1 Characteristics of the study population based on hemoglobin A1C (HbA1c) level quintiles
HbA1c level quintiles
Q1 (low) Q2 Q3 Q4 Q5 (high) P
Hemoglobin A1c (HbA1c) median values, % 5.04 5.35 5.45 5.76 6.17
Total subjects
No. at risk 190 205 258 246 251
Age, year 70.3 ± 6.3 70.5 ± 7.6 70.3 ± 6.7 70.7 ± 7.0 70.3 ± 7.0
Systolic blood pressure, mmHg 144 ± 20 147 ± 22 143 ± 19 143 ± 19 146 ± 22 0.107
Antihypertensive medication use, % 35.8 30.2 38.8 35.8 40.6 0.165
Body mass index, kg/m2 22.8 ± 2.8 23.5 ± 3.1 23.1 ± 2.8 23.9 ± 2.9 24.2 ± 3.4 <0.001
Current drinker, % 53.2 52.2 51.6 42.3 44.2 0.058
Current smoker, % 20.5 17.6 24.0 17.5 19.5 0.381
Serum triglycerides, mg/dL 98 ± 50 119 ± 80 105 ± 58 129 ± 82 134 ± 98 <0.001
Serum HDL-cholesterol, mg/dL 56 ± 15 54 ± 14 56 ± 15 53 ± 14 53 ± 15 0.059
Serum aspartate aminotransferase (AST), IU/L 25 ± 12 25 ± 9 24 ± 7 25 ± 8 27 ± 13 0.033
Glucose-lowering medication use, % 2.1 2.0 1.2 2.8 27.9 <0.001
Lipid-lowering medication use, % 3.2 5.9 5.4 7.7 10.8 0.020
History of cardiovascular disease, % 9.5 8.3 12.4 15.9 16.3 0.033
Taking medication for cardiovascular disease, % 7.4 7.3 11.2 14.6 14.3 0.025
Serum creatinine, mg/dL 0.98 ± 0.32 0.92 ± 0.28 0.92 ± 0.29 0.88 ± 0.22 0.88 ± 0.22 <0.001
Glomerular filtration rate (GFR), mL/min/1.73 m2 63.7 ± 17.9 67.2 ± 17.6 67.6 ± 17.2 69.5 ± 16.4 70.5 ± 16.8 <0.001
Low body mass index (BMI)
No. at risk 103 102 127 98 90
Age, year 71.5 ± 6.7 71.5 ± 8.1 70.2 ± 7.2 71.6 ± 7.3 70.7 ± 7.2
Systolic blood pressure, mmHg 140 ± 21 142 ± 20 140 ± 18 138 ± 17 140 ± 22 0.543
Antihypertensive medication use, % 28.2 25.5 29.1 23.5 25.6 0.778
Body mass index, kg/m2 20.8 ± 1.5 20.9 ± 1.5 20.8 ± 1.7 21.1 ± 1.5 20.7 ± 1.6 0.429
Current drinker, % 60.2 50.0 50.2 48.2 49.0 0.004
Current smoker, % 23.3 20.6 29.9 21.4 21.1 0.524
Serum triglycerides, mg/dL 90 ± 52 101 ± 55 93 ± 50 107 ± 66 103 ± 66 0.175
Serum HDL-cholesterol, mg/dL 60 ± 15 56 ± 14 58 ± 15 56 ± 15 57 ± 16 0.370
Serum aspartate aminotransferase (AST), IU/L 26 ± 14 25 ± 9 23 ± 5 25 ± 9 25 ± 10 0.328
Glucose-lowering medication use, % 3.9 2.9 0.8 10.2 30.0 <0.001
Lipid-lowering medication use, % 2.9 5.9 4.7 8.2 5.6 0.573
History of cardiovascular disease, % 7.8 4.9 8.7 14.3 16.7 0.032
Taking medication for cardiovascular disease, % 5.8 3.9 7.8 13.3 12.2 0.068
Serum creatinine, mg/dL 1.00 ± 0.37 0.94 ± 0.35 0.91 ± 0.34 0.85 ± 0.16 0.88 ± 0.25 0.006
GFR, mL/min/1.73 m2 62.4 ± 17.0 68.0 ± 20.6 69.6 ± 18.5 71.1 ± 14.7 70.1 ± 17.3 0.004
High BMI
No. at risk 87 103 131 148 161
Age, year 68.9 ± 5.6 69.5 ± 6.9 70.4 ± 6.1 70.2 ± 6.8 70.1 ± 7.2
Systolic blood pressure, mmHg 149 ± 17 152 ± 23 147 ± 19 146 ± 20 150 ± 21 0.154
Antihypertensive medication use, % 44.8 35.0 48.1 43.9 49.1 0.258
Body mass index, kg/m2 25.1 ± 1.9 26.0 ± 2.1 25.4 ± 1.7 25.7 ± 1.8 26.1 ± 2.5 0.001
Current drinker, % 44.8 54.4 55.0 46.6 47.2 0.296
Current smoker, % 17.2 14.6 18.3 14.9 18.6 0.822
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Table 1 Characteristics of the study population based on hemoglobin A1C (HbA1c) level quintiles (Continued)
Serum triglycerides, mg/dL 106 ± 45 137 ± 96 116 ± 62 143 ± 88 152 ± 108 <0.001
Serum HDL-cholesterol, mg/dL 51 ± 14 52 ± 15 54 ± 14 51 ± 12 51 ± 13 0.300
Serum aspartate aminotransferase (AST), IU/L 24 ± 10 26 ± 10 24 ± 8 25 ± 8 28 ± 15 0.021
Glucose-lowering medication use, % 0.0 1.0 1.5 4.1 26.7 <0.001
Lipid-lowering medication use, % 3.4 5.8 6.1 7.4 13.7 0.028
History of cardiovascular disease, % 11.5 11.7 16.0 16.9 16.1 0.770
Taking medication for cardiovascular disease, % 9.2 10.7 14.5 15.5 15.5 0.645
Serum creatinine, mg/dL 0.96 ± 0.26 0.91 ± 0.18 0.93 ± 0.23 0.91 ± 0.25 0.87 ± 0.20 0.021
GFR, mL/min/1.73 m2 65.3 ± 18.8 66.5 ± 14.0 65.6 ± 15.5 68.4 ± 17.4 70.5 ± 16.2 0.021
Low BMI consists of BMI <23 kg/m2 and high BMI consists of BMI ≥23 kg/m2. P: age-adjusted values of P for the trend.
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the finding from our present study that among subjects
not taking glucose-lowering medication or medication
for hyperlipidemia and cardiovascular disease, the high-
est HbA1c levels (Q5) showed a significant risk of ca-
rotid atherosclerosis in subjects with high BMI but not
in those with low BMI. However, no significant inter-
action between HbA1c and BMI status with regard to
carotid atherosclerosis was observed in the HbA1c
(≥Q3) group as a result of this higher risk of carotid ath-
erosclerosis with higher HbA1c levels (Q4) in subjects
with low BMI but not in subjects with high BMI. To
clarify the influence of BMI on the association between
carotid atherosclerosis and HbA1c among subjects with
HbA1c (≥Q3), further investigation with a larger popula-




No. at risk 190 205
No. of cases (percentage) 57 (30.0) 64 (31.2)
Age-adjusted odds ratio (OR) 1.24 (0.81 to 1.90) 1.28 (0.84 to
Multivariable OR 1.21 (0.78 to 1.88) 1.36 (0.88 to
Low BMI
No. at risk 103 102
No. of cases (percentage) 35 (34.0) 35 (34.3)
Age-adjusted OR 2.01 (1.08 to 3.73) 2.01 (1.07 to
Multivariable OR 1.78 (0.92 to 3.44) 2.05 (1.06 to
High BMI
No. at risk 87 103
No. of cases (percentage) 22 (25.3) 29 (28.2)
Age-adjusted OR 0.78 (0.42 to 1.45) 0.86 (0.49 to
Multivariable OR 0.66 (0.35 to 1.27) 0.94 (0.51 to
Multivariable: adjusted further for age, systolic blood pressure, antihypertensive medicatio
cardiovascular disease, use of glucose-lowering medication, lipid-lowering medication use
(AST), and estimated glomerular filtration rate (GFR). Low body mass index (BMI) consistsMechanisms explaining why lower HbA1c levels lead
to a significant risk of atherosclerosis have not been elu-
cidated. A previous study on type 1 diabetes reported
episodes of hypoglycemia (<70 mg/dL) as a potential ag-
gravating factor for preclinical atherosclerosis [20], and
repeated episodes of hypoglycemia may perform a cru-
cial role for this association. Since another study re-
ported that chronic kidney disease is a risk factor for
hypoglycemia (<70 mg/dL) and this association was ob-
served both in subjects with or without diabetes [21],
those with reduced GFR may demonstrate a frequency
of hypoglycemia that results in lower HbA1c levels. Fur-
ther investigations we had conducted on subjects with
HbA1c (≤Q3) showed a significant inverse association
between estimated GFR and HbA1c in subjects with low
BMI but not in those with high BMI. On the other hand,(HbA1c) levels
Q3 Q4 Q5 (high)
258 246 251
67 (26.0) 71 (28.9) 83 (33.1)
1.95) 1.00 1.13 (0.76 to 1.68) 1.42 (0.94 to 2.10)
2.11) 1.00 1.13 (0.82 to 2.01) 1.13 (0.74 to 1.71)
127 98 90
25 (19.7) 27 (27.6) 21 (23.3)
3.75) 1.00 1.44 (0.76 to 2.72) 1.23 (0.63 to 2.40)
3.96) 1.00 1.55 (0.77 to 3.09) 1.26 (0.58 to 2.76)
131 148 161
42 (32.1) 44 (29.7) 62 (38.5)
1.53) 1.00 0.90 (0.54 to 1.51) 1.35 (0.83 to 2.22)
1.73) 1.00 0.91 (0.53 to 1.55) 1.26 (0.72 to 2.22)
n use, body mass index, smoking, alcohol intake, taking medication for
, serum triglyceride (TG), serum HDL-cholesterol, serum aspartate aminotransferase
of BMI <23 kg/m2 and high BMI consists of BMI ≥23 kg/m2.
Table 3 Age-adjusted characteristics of the study population limited to subjects with HbA1c (≤Q3)
Total subjects Low BMI High BMI
HbA1c level quintiles HbA1c level quintiles HbA1c level quintiles
Q1 (low) Q2 Q3 (high) P Q1 (low) Q2 Q3 (high) P Q1 (low) Q2 Q3 (high) P
No. at risk 190 205 258 103 102 127 87 103 131
Age, year 70.3 ± 6.3 70.5 ± 7.6 70.3 ± 6.7 71.5 ± 6.7 71.5 ± 8.1 70.2 ± 7.2 68.9 ± 5.6 69.5 ± 6.9 70.4 ± 6.1
Systolic blood pressure, mmHg 144 147 143 0.187 140 142 140 0.721 149 152 147 0.223
Antihypertensive medication use, % 35.9 30.1 38.9 0.132 27.4 24.8 30.3 0.642 46.1 35.2 47.0 0.144
Body mass index, kg/m2 22.8 23.5 23.1 0.062 20.8 20.9 20.8 0.674 25.1 26.0 25.4 0.008
Current drinker, % 53.1 52.3 51.5 0.942 60.6 50.4 47.4 0.121 43.7 54.1 55.9 0.179
Current smoker, % 20.5 17.6 24.0 0.242 23.8 21.0 29.2 0.334 16.8 14.5 18.7 0.692
Serum triglycerides, mg/dL 97 119 105 0.003 91 101 92 0.284 105 137 117 0.010
Serum HDL-cholesterol, mg/dL 56 54 56 0.319 60 56 58 0.157 51 52 54 0.321
Serum aspartate aminotransferase
(AST), IU/L
25 25 24 0.263 26 25 23 0.127 24 26 24 0.322
Glucose-lowering medication use, % 2.1 2.0 1.2 0.699 3.9 3.0 0.8 0.279 0.0 1.0 1.6 0.481
Lipid-lowering medication use, % 3.2 5.9 5.4 0.410 2.9 5.9 4.7 0.589 3.4 5.8 6.1 0.659
History of cardiovascular disease, % 9.5 8.2 12.4 0.302 7.6 4.7 8.9 0.471 12.2 11.8 15.4 0.675
Taking medication for cardiovascular disease, % 7.4 7.3 11.3 0.218 5.6 3.7 8.2 0.354 9.8 10.8 14.0 0.585
Serum creatinine, mg/dL 0.98 0.92 0.92 0.055 1.00 0.93 0.92 0.193 0.96 0.91 0.93 0.334
Glomerular filtration rate (GFR), mL/min/1.73 m2 63.7 67.3 67.5 0.036 62.7 68.4 69.0 0.020 64.8 66.4 66.0 0.792












Table 4 Carotid atherosclerosis in relation to hemoglobin A1c (HbA1c) levels in subjects not taking medication
HbA1c level quintiles
Q1 (low) Q2 Q3 Q4 Q5 (high)
Total subject
No. at risk 168 180 216 192 138
No. of cases (percentage) 51 (30.4) 54 (30.0) 51 (23.6) 54 (28.1) 46 (33.3)
Age-adjusted odds ratio (OR) 1.42 (0.89 to 2.26) 1.35 (0.85 to 2.13) 1.00 1.26 (0.80 to 1.98) 1.62 (1.00 to 2.63)
Multivariable OR 1.36 (0.84 to 2.20) 1.44 (0.89 to 2.33) 1.00 1.30 (0.80 to 2.10) 1.58 (0.94 to 2.66)
Low body mass index (BMI)
No. at risk 92 91 111 78 50
No. of cases (percentage) 33 (35.9) 29 (31.9) 20 (18.0) 19 (24.4) 10 (20.0)
Age-adjusted OR 2.40 (1.24 to 4.67) 2.04 (1.03 to 4.01) 1.00 1.42 (0.69 to 2.91) 1.13 (0.48 to 2.67)
Multivariable OR 2.29 (1.12 to 4.66) 2.15 (1.05 to 4.39) 1.00 1.50 (0.67 to 3.33) 0.99 (0.39 to 2.53)
High BMI
No. at risk 76 89 105 114 88
No. of cases (percentage) 18 (23.7) 25 (28.1) 31 (29.5) 35 (30.7) 36 (40.9)
Age-adjusted OR 0.80 (0.41 to 1.59) 0.93 (0.49 to 1.74) 1.00 1.07 (0.59 to 1.92) 1.66 (0.90 to 3.05)
Multivariable OR 0.68 (0.33 to 1.41) 1.09 (0.55 to 2.16) 1.00 1.19 (0.64 to 2.21) 2.01 (1.04 to 3.90)
Multivariable: adjusted further for age, systolic blood pressure, antihypertensive medication use, body mass index, smoking, alcohol intake, serum triglyceride (TG),
serum HDL-cholesterol, serum aspartate aminotransferase (AST), and estimated glomerular filtration rate (GFR). Low BMI consists of BMI <23 kg/m2 and high BMI
consists of BMI ≥23 kg/m2.
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lial function [22], and endothelial dysfunction has been
recognized as one of the initial mechanisms leading to
glomerular injury [23] and atherosclerosis. Lower HbA1c
levels may be associated both with carotid atheroscler-
osis and reduced GFR by indicating a higher frequency
of low-glucose exposure. A previous study reporting that
not only higher but also lower levels of HbA1c are asso-
ciated with a higher risk of death for subjects with dia-
betes and chronic kidney disease partially supports our
results [5]. However, the reason why this significant as-
sociation of lower HbA1c with carotid atherosclerosis
was restricted to subjects with low BMI has not yet been
clarified. Subjects with low-BMI and low-HbA1c level
might have a higher risk of hypoglycemia compared to
subjects with high BMI and low HbA1c. Further investi-
gations are necessary to clarify these associations.
Since the association between regular alcohol intake
and incidence of carotid atherosclerosis was reported to
be J-shaped (with light drinkers facing a lower risk than
either heavy drinkers or abstainers) [24], alcohol intake
might also influence the association between HbA1c
level and carotid atherosclerosis. In our study, even
though the statistical power did not reach the level of
significance, HbA1c levels were inversely associated with
current-drinker status in subjects with low BMI but not
in subjects with high BMI. Further investigations using
detailed alcohol consumption data are necessary.Limitations
Potential limitations in our study warrant consideration.
Even though we found in a study limited to subjects not
taking glucose-lowing medication or medication for
hyperlipidemia and cardiovascular disease that the high-
est HbA1c levels represent a significant risk for carotid
atherosclerosis in subjects with high but not with low
BMI, the interaction between height and BMI category
for these subjects did not reach the level of significance,
with a multivariable adjusted P value of 0.474 for the ef-
fect of this interaction on carotid atherosclerosis. Fur-
ther studies using larger numbers of subjects will be
necessary to determine the reason for this finding.
Moreover, we could not evaluate the frequency of
hypoglycemia for the low-HbA1c group, which might
have been higher in subjects with low BMI than in those
with high BMI. A further clinical study using daily blood
sugar data to evaluate daily variations will thus be neces-
sary. Since we did not have detailed data on medications
for cardiovascular diseases such as antithrombotic ther-
apy and/or anticoagulation therapy, which might have a
strong effect on the progression of atherosclerosis, ad-
justments for these medications are of limited value.
However, further investigations restricted to subjects
who were not taking medication for cardiovascular dis-
ease showed significant associations. Finally, because this
was a cross-sectional study, no causal relationships could
be established.
Shimizu et al. Journal of Physiological Anthropology  (2015) 34:16 Page 8 of 8Conclusion
In conclusion, lower HbA1c levels constitute a signifi-
cant risk for carotid atherosclerosis in subjects with low
BMI but not in subjects with high BMI as shown in rural
community-dwelling elderly Japanese men, particularly
in those that do not take glucose-lowering medications.
Consent
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